AusperBio
AusperBio is a clinical-stage biopharmaceutical company operating in the USA and China, focused on developing transformative oligonucleotide therapies, particularly targeting a functional cure for chronic hepatitis B. Utilizing its proprietary Med-Oligo™ ASO platform, the company enhances antisense oligonucleotide therapeutics, aiming to address a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
Leadership & Board
- Current Number of Employees
- 11
- Current LinkedIn Followers
- 1,505
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $186M
- Total Funding Rounds
- 3
- Latest Funding Amount
- $63M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Employee Trend
AusperBio had 11 employees as of October 12, 2026. The number of employees increased by 1 (10.00%) week-over-week.
Social Trend
AusperBio had 1,505 followers as of October 12, 2026. The number of followers increased by 112 (8.04%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 22, 2025 | Series B | $63.00M | ― |
| Aug 14, 2025 | Series B | $73.00M | ― |
| May 28, 2025 | Series B | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Qiming Venture Partners | Series B (2) |
| Yuanbio Venture Capital | Series B (2) |
| CDH Investments | Series B (2) |
| Genesis Capital | Series B (2) |
| HanKang Capital | Series B (2) |
| Sherpa Capital | Series B (2) |
Similar Companies
A snapshot of private companies similar to AusperBio, helping you discover and navigate related company profiles.
Related News and Analysis
